Generali Investments Management Co LLC Buys New Shares in Regeneron Pharmaceuticals, Inc. $REGN

Generali Investments Management Co LLC bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,202 shares of the biopharmaceutical company’s stock, valued at approximately $676,000.

Other hedge funds have also recently bought and sold shares of the company. Osaic Holdings Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 55.2% in the 2nd quarter. Osaic Holdings Inc. now owns 17,068 shares of the biopharmaceutical company’s stock valued at $9,607,000 after buying an additional 6,073 shares during the last quarter. Robeco Institutional Asset Management B.V. increased its holdings in Regeneron Pharmaceuticals by 153.4% during the third quarter. Robeco Institutional Asset Management B.V. now owns 120,884 shares of the biopharmaceutical company’s stock worth $67,969,000 after buying an additional 73,176 shares during the last quarter. PGGM Investments raised its position in Regeneron Pharmaceuticals by 9.7% during the third quarter. PGGM Investments now owns 92,584 shares of the biopharmaceutical company’s stock worth $52,057,000 after acquiring an additional 8,187 shares in the last quarter. Rakuten Investment Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at $33,121,000. Finally, Sound Shore Management Inc CT bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $64,677,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock opened at $770.79 on Friday. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $81.49 billion, a price-to-earnings ratio of 18.55, a price-to-earnings-growth ratio of 2.11 and a beta of 0.40. The company has a 50-day simple moving average of $771.32 and a two-hundred day simple moving average of $679.14. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue was up 2.5% on a year-over-year basis. During the same quarter last year, the company earned $12.07 EPS. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Friday, February 20th. This represents a $3.76 annualized dividend and a yield of 0.5%. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is 9.05%.

Insider Activity

In other news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 46.83% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the transaction, the director directly owned 17,803 shares in the company, valued at $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 5,274 shares of company stock valued at $4,142,738 over the last quarter. 7.02% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

REGN has been the topic of a number of research analyst reports. Scotiabank upped their target price on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the company a “sector perform” rating in a report on Monday, November 24th. Oppenheimer restated an “outperform” rating and issued a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Canaccord Genuity Group lifted their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Wall Street Zen lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, February 16th. Finally, Evercore raised their price target on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $793.81.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.